Individuals from the Asian sub-continent in the United Kingdom are at particular risk of developing osteomalacia. We report a Gujarati woman who developed osteomalacia whilst taking anticonvulsant drugs; withdrawal of anticonvulsant therapy was followed by a seizure complicated by femoral neck fracture.
Introduction
Osteomalacia is one of a number of complications that may develop during the long-term use of anticonvulsant drugs.' The majority of such adverse effects, including osteomalacia, are benefitted by discontinuing the drugs. If, however, a seizure occurs shortly after anticonvulsant drugs are withdrawn in an individual with osteomalacia the skeleton is likely to be at considerable risk.
We describe a patient on anticonvulsant drugs in whom the diagnosis of osteomalacia was made and appropriate treatment given. Unfortunately, cessation of the anticonvulsant drugs was followed by a seizure which, because insufficient time had been allowed for the bones to heal, was associated with a fracture. This case has implications for patients with major epilepsy in whom withdrawal of anticonvulsant therapy is being considered, particularly if there are other risk factors for the development of osteomalacia. D2 and at the same time the anticonvulsant drugs were discontinued. Four days later she suffered a grand mal convulsion resulting in sub-capital fracture of the right femoral neck. Treatment by internal fixation resulted in healing of the fracture but the patient subsequently developed avascular necrosis of the femoral head ( Figure 1 ).
Eleven years later, she presented with back and thigh pain and was found to have radiological and biochemical evidence of osteomalacia once again. In our patient, the fact that she took a traditional Gujarati diet and kept her arms and legs fully covered throughout the year undoubtedly contributed to her metabolic bone disease.6'7
As she had been seizure-free for 10 years and a major complication of drug therapy had arisen it was considered appropriate both to discontinue anticonvulsant treatment and at the same time to start vitamin D therapy. In the light of subsequent events, however, it would have been advisable to have ensured adequate treatment of her metabolic bone disease before withdrawing the anticonvulsant drugs.
In individuals in whom a reduction or withdrawal of anticonvulsant therapy is being considered, especially in those originating from the Indian sub-continent, it is particularly important to consider and rule out this form, and indeed any other form, of metabolic bone disease. In practice this may not be easy since many patients on phenytoin, for example, have raised serum alkaline phosphatase levels. In such a patient the absence of a raised bone component in combination with a normal plasma calcium and phosphate would normally be sufficient to rule out significant osteomalacia. 8 It should be remembered that hypocalcaemia increases neuromuscular excitability so that individuals with unsuspected osteomalacia may actually be more likely than those with normal bones to have a seizure when anticonvulsant drugs are withdrawn.
Femoral neck fracture has been reported as a complication of hypocalcaemic seizures in an Asian woman, in whom hypocalcaemia was induced by lactation9 and earlier, in patients following parathyroidectomy.'°In our patient too, hypocalcaemia may have contributed to the seizure. Clearly, if the osteomalacia had been treated well before the drugs were discontinued there might not have been a seizure and fracture risk would have been negligible.
Where deficiency of vitamin D is suspected, repletion should be ensured before anticonvulsant drugs are stopped. Higher doses than usual of vitamin D may be required in these patients because of increased hepatic enzyme activity. A recent study showed healing of the bone, measured by return to normal of alkaline phosphatase activity, in 42% of children on anticonvulsant drugs after 6 
